MoonLake Immunotherapeutics
IZAR-1
psoriatic arthritis
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for IZAR-1 in psoriatic arthritis are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Disclosures expected in a Q3 2026 press release, incl. "met" vs. "did not meet" endpoint reference”